Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for efficiently and rapidly evaluating prognosis of II-stage colorectal cancer patient based on immune gene expression characteristic spectrum

A colorectal cancer, gene expression technology, applied in the medical field, can solve problems such as the controversy over the benefits of chemotherapy, and achieve a good prediction effect.

Inactive Publication Date: 2021-07-02
THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although postoperative adjuvant chemotherapy is now the standard treatment for stage III CRC, the benefit of chemotherapy in stage II CRC remains controversial

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for efficiently and rapidly evaluating prognosis of II-stage colorectal cancer patient based on immune gene expression characteristic spectrum
  • Method for efficiently and rapidly evaluating prognosis of II-stage colorectal cancer patient based on immune gene expression characteristic spectrum
  • Method for efficiently and rapidly evaluating prognosis of II-stage colorectal cancer patient based on immune gene expression characteristic spectrum

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1: The steps of the method for constructing the IRGCRCⅡ prognosis model are as follows:

[0033] S1: Acquisition of patient information: Obtain the gene expression profile (data level 3) and clinical data of CRC patients from the TCGA database; obtain the transcriptome data and clinical data of stage II CRC that meet the diagnostic criteria in the GSE39582 microarray data set from the GEO database; obtain from the ImmPort Immune-related genes (IRGs) were obtained in the database; patients selected from the GSE39582 data set of the TCGA database and the GEO database were screened for cancers that met the diagnostic criteria for stage II CRC patients determined by the American Joint Committee on Cancer (AJCC) 8th edition. Among the patients included in the analysis, there were 201 cases from the TCGA database and 466 cases from the GSE39582 data set of the GEO database (see Table 1); the above clinical data included age, gender, tumor stage, chemotherapy, surviv...

Embodiment 2

[0050] Example 2: Comparison of the IRGCRCⅡ prognosis model of the present invention with the OncotypeDX colon model

[0051] In order to further evaluate the accuracy of the IRGCRC II prognosis model in predicting the survival rate, this example compared it with the OncotypeDX colon model, the most widely used gene marker in stage II CRC bowel cancer. ROC analysis was performed on the training cohort using both models to evaluate the sensitivity and specificity of survival prediction. The AUCs of the IRGCRCⅡ prognosis model were significantly higher than those of the OncotypeDX colon model at 1 year (0.759vs.0.623), 3 years (0.875vs.0.629) and 5 years (0.906vs.0.698), indicating that the IRGCRCⅡ model has better prognosis accuracy sex( Figure 5 C-E).

Embodiment 3

[0052] Example 3: Relationship between IRGCRCⅡ prognosis model and clinicopathological features

[0053] In order to further evaluate the role of the IRGCRCII model in predicting prognosis, this example incorporates the IRGCRCII risk score and some common clinicopathological features such as age, sex, T stage and chemotherapy into the prognostic correlation analysis. In the training group, univariate Cox regression analysis showed that age, chemotherapy, and risk score were significantly associated with patient survival ( Image 6 A). Multivariate Cox regression analysis showed age (hazard ratio (HR) = 1.034, 95% confidence interval (CI) = 1.000–1.068, p = 0.047) and risk score (HR = 1.184, 95% CI = 1.113–1.260, p Image 6 B). In the overall group, the risk score can be used as an independent prognostic factor for stage II CRC by univariate and multivariate Cox analysis in this embodiment ( Figure 7 A-B).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for efficiently and rapidly evaluating the prognosis of a patient with stage II colorectal cancer based on an immune gene expression characteristic spectrum and a construction method of an IRGCRC II prognosis model; the IRGCRC II prognosis model is adopted to evaluate the prognosis of the patient with stage II colorectal cancer, and the IRGCRC II prognosis model comprises CCL28, FGF18, IL23A, LIF, SLIT2 and VGF immune genes. According to the IRGCRC II prognosis model constructed by the invention, a gene model tool for evaluating the prognosis of the II-stage CRC patient is constructed on the basis of the content determination of six immune genes in the body of the II-stage colorectal cancer patient with high expression, and a new evaluation system is provided for evaluating the survival outcome of the II-stage colorectal cancer patient; and a new basis is provided for selection of treatment schemes such as whether the patient is subjected to chemical treatment or not.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to a method for efficiently and quickly evaluating the prognosis of stage II colorectal cancer patients based on immune gene expression profiles. Background technique [0002] Colorectal cancer (CRC) is the third most common cancer worldwide and the leading cause of cancer-related death, with 1.8 million new cases and 880,000 CRC patient deaths in 2018 alone. Surgery is the basis for the treatment of colorectal cancer, but about 20% of stage Ⅱ CRC patients relapse after surgery. Although postoperative adjuvant chemotherapy is now the standard treatment for stage III CRC, the benefit of chemotherapy in stage II CRC remains controversial. Therefore, it is necessary to construct new features to predict different prognosis and help to select appropriate treatment options in stage II CRC. The tumor immune microenvironment is closely related to the occurrence and development of tumors,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G16H50/50G16H50/70G16B20/00
CPCG16H50/50G16H50/70G16B20/00
Inventor 练磊殷实李宪哲谢明颢熊志中
Owner THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com